Go Pro
→ Elon did WHAT?! (From Brownstone Research) (Ad)tc pixel Free ABDX Stock Alerts

Abingdon Health (ABDX) Competitors

Abingdon Health logo
GBX 9.50 -0.25 (-2.56%)
As of 07/24/2026 12:25 PM Eastern
Compare

ABDX vs. GDR, YGEN, VRCI, AGL, and PRM

Should you buy Abingdon Health stock or one of its competitors? MarketBeat compares Abingdon Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abingdon Health include genedrive (GDR), Yourgene Health (YGEN), Verici Dx (VRCI), ANGLE (AGL), and Proteome Sciences (PRM). These companies are all part of the "diagnostics & research" industry.

How does Abingdon Health compare to genedrive?

Abingdon Health (LON:ABDX) and genedrive (LON:GDR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 8.0% of Abingdon Health shares are held by insiders. Comparatively, 29.0% of genedrive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Abingdon Health has a net margin of -33.88% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -55.91% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
genedrive -500.75%-1,044.57%-74.09%

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled genedrive'saverage media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
genedrive Neutral

Abingdon Health has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, genedrive has a beta of 0.989, indicating that its share price is 1% less volatile than the broader market.

Abingdon Health has higher revenue and earnings than genedrive. Abingdon Health is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.49-£796.37K-£0.81N/A
genedrive£929K17.63-£21.22M-£0.79N/A

Summary

Abingdon Health beats genedrive on 6 of the 11 factors compared between the two stocks.

How does Abingdon Health compare to Yourgene Health?

Abingdon Health (LON:ABDX) and Yourgene Health (LON:YGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
Yourgene Health Neutral

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 23.3% of Yourgene Health shares are held by institutional investors. 8.0% of Abingdon Health shares are held by insiders. Comparatively, 64.4% of Yourgene Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abingdon Health has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Abingdon Health has higher earnings, but lower revenue than Yourgene Health. Abingdon Health is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.49-£796.37K-£0.81N/A
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A

Yourgene Health has a net margin of -27.55% compared to Abingdon Health's net margin of -33.88%. Yourgene Health's return on equity of -27.06% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
Yourgene Health -27.55%-27.06%-6.71%

Summary

Yourgene Health beats Abingdon Health on 8 of the 10 factors compared between the two stocks.

How does Abingdon Health compare to Verici Dx?

Verici Dx (LON:VRCI) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Abingdon Health has a net margin of -33.88% compared to Verici Dx's net margin of -193.05%. Abingdon Health's return on equity of -55.91% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
Abingdon Health -33.88%-55.91%-17.93%

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company Overall Sentiment
Verici Dx Neutral
Abingdon Health Neutral

Verici Dx has a beta of 1.256, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Abingdon Health has higher revenue and earnings than Verici Dx. Abingdon Health is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M2.45-£6.56M-£0.90N/A
Abingdon Health£9.57M2.49-£796.37K-£0.81N/A

7.9% of Verici Dx shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 1.3% of Verici Dx shares are owned by company insiders. Comparatively, 8.0% of Abingdon Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Abingdon Health beats Verici Dx on 8 of the 11 factors compared between the two stocks.

How does Abingdon Health compare to ANGLE?

Abingdon Health (LON:ABDX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.49-£796.37K-£0.81N/A
ANGLE£2.62M2.89-£21.76M-£4.80N/A

Abingdon Health has a net margin of -33.88% compared to ANGLE's net margin of -1,444.04%. Abingdon Health's return on equity of -55.91% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
ANGLE -1,444.04%-191.36%-29.89%

In the previous week, ANGLE's average media sentiment score of 0.75 beat Abingdon Health's score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.

Company Overall Sentiment
Abingdon Health Neutral
ANGLE Positive

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 17.5% of ANGLE shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by insiders. Comparatively, 2.7% of ANGLE shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abingdon Health has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

Summary

Abingdon Health beats ANGLE on 7 of the 12 factors compared between the two stocks.

How does Abingdon Health compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Abingdon Health has higher revenue and earnings than Proteome Sciences. Abingdon Health is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.49-£4.08M-£1.04N/A
Abingdon Health£9.57M2.49-£796.37K-£0.81N/A

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Abingdon Health Neutral

Abingdon Health has a net margin of -33.88% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Abingdon Health -33.88%-55.91%-17.93%

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by insiders. Comparatively, 8.0% of Abingdon Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Proteome Sciences has a beta of 0.148, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Summary

Abingdon Health beats Proteome Sciences on 8 of the 11 factors compared between the two stocks.

Get Abingdon Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABDX vs. The Competition

Export
MetricAbingdon HealthDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£24.48M£671.92M£7.06B£2.75B
Dividend YieldN/A3.32%2.67%6.15%
P/E Ratio-11.7369.3027.14368.39
Price / Sales2.49572.97582.3084,479.14
Price / Cash2.2511.4249.8127.89
Price / Book13.053.0710.287.41
Net Income-£796.37K£334.07B£3.60B£5.89B
7 Day Performance-2.56%-0.51%-1.27%0.39%
1 Month Performance-6.40%-0.30%-1.67%0.27%
1 Year Performance52.98%5.83%18.25%68.12%

Abingdon Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABDX
Abingdon Health
N/AGBX 9.50
-2.6%		N/A+53.0%£24.48M£9.57MN/A84
GDR
genedrive
N/AGBX 1.08
-10.0%		N/A-24.4%£17.34M£929KN/A43
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
VRCI
Verici Dx
N/AGBX 0.30
-14.3%		N/A-45.5%£8.96M£3.66MN/A19
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-60.8%£7.58M£2.62MN/A650

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:ABDX) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
When governments buy their own debt, gold miners move
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel